Dopamine and stress system modulation of sex differences in decision making
PublisherNature Publishing Group
MetadataShow full item record
AbstractMaladaptive decision making is associated with several neuropsychiatric disorders, including problem gambling and suicidal behavior. The prevalence of these disorders is higher in men vs women, suggesting gender-dependent regulation of their pathophysiology underpinnings. We assessed sex differences in decision making using the rat version of the Iowa gambling task. Female rats identified the most optimal choice from session 1, whereas male rats from session 5. Male, but not female rats, progressively improved their advantageous option responding and surpassed females. Estrus cycle phase did not affect decision making. To test whether pharmacological manipulations targeting the dopaminergic and stress systems affect decision making in a sex-dependent manner, male and female rats received injections of a dopamine D2 receptor (D2R) antagonist (eticlopride), D2R agonist (quinpirole), corticotropin-releasing factor 1 (CRF1) antagonist (antalarmin), and α2-adrenergic receptor antagonist (yohimbine; used as a pharmacological stressor). Alterations in mRNA levels of D2R and CRF1 were also assessed. Eticlopride decreased advantageous responding in male, but not female rats, whereas quinpirole decreased advantageous responding specifically in females. Yohimbine dose-dependently decreased advantageous responding in female rats, whereas decreased advantageous responding was only observed at higher doses in males. Antalarmin increased optimal choice responding only in female rats. Higher Drd2 and Crhr1 expression in the amygdala were observed in female vs male rats. Higher amygdalar Crhr1 expression was negatively correlated with advantageous responding specifically in females. This study demonstrates the relevance of dopaminergic- and stress-dependent sex differences to maladaptive decision making. Copyright 2018 American College of Neuropsychopharmacology.
SponsorsThis work was supported by Maryland Department of health and Mental Hygiene, Behavioral Health Administration, Grant # M00B4400404 and National Institute of Health 5R01MH091816.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046676895&doi=10.1038%2fnpp.2017.161&partnerID=40&md5=58c0f9ec5781b697ea86636935b3ef84; http://hdl.handle.net/10713/9267
- The CRF1 receptor antagonist, antalarmin, reverses isolation-induced up-regulation of dopamine D2 receptors in the amygdala and nucleus accumbens of fawn-hooded rats.
- Authors: Djouma E, Card K, Lodge DJ, Lawrence AJ
- Issue date: 2006 Jun
- Dopaminergic modulation of risk-based decision making.
- Authors: St Onge JR, Floresco SB
- Issue date: 2009 Feb
- Alterations in effort-related decision-making induced by stimulation of dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, and corticotropin-releasing factor receptors in nucleus accumbens subregions.
- Authors: Bryce CA, Floresco SB
- Issue date: 2019 Sep
- Modulation of risk/reward decision making by dopaminergic transmission within the basolateral amygdala.
- Authors: Larkin JD, Jenni NL, Floresco SB
- Issue date: 2016 Jan
- The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.
- Authors: Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y, Lê AD
- Issue date: 2007 Dec